Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: …
この記事を読む
記事一覧 29ページ
この記事を読む
ADAと免疫療法
Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Saiki M et…
この記事を読む
HPDは疲弊T細胞と関連する
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG, Ann Oncol. 2019…
この記事を読む
輸血の既往が予後を変える？
Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Sa…
この記事を読む
アファチニブのlast resort
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Schu…
この記事を読む
ICIにおける脳転移の予後
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Hendriks LE…
この記事を読む
EGFR-TKIへの耐性機序としてのBRAF rearrangements
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Vojnic M et al. J…
この記事を読む
KRAS陽性に対する免疫治療
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A et al. J Thorac On…
この記事を読む
免疫チェックポイント阻害薬の後、すぐにオシメルチニブは危険
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Schoenfeld AJ et al. A…
この記事を読む
抗生物質投与と免疫療法
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Galli …